213 related articles for article (PubMed ID: 20040526)
1. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
[TBL] [Abstract][Full Text] [Related]
3. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
[TBL] [Abstract][Full Text] [Related]
4. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
5. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
6. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
7. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
Rosato E; Molinaro I; Borghese F; Rossi C; Pisarri S; Salsano F
J Rheumatol; 2010 Dec; 37(12):2531-9. PubMed ID: 20810512
[TBL] [Abstract][Full Text] [Related]
8. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of bosentan in the treatment of Raynaud's phenomenon in patients with systemic sclerosis never treated with prostanoids.
Parisi S; Bruzzone M; Centanaro Di Vittorio C; Laganà A; Peroni CL; Fusaro E
Reumatismo; 2014 Mar; 65(6):286-91. PubMed ID: 24705032
[TBL] [Abstract][Full Text] [Related]
10. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
11. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
12. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon.
Moore TL; Vail A; Herrick AL
Rheumatology (Oxford); 2007 Feb; 46(2):363-4. PubMed ID: 17116656
[No Abstract] [Full Text] [Related]
13. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis.
Taniguchi T; Asano Y; Hatano M; Tamaki Z; Tomita M; Kawashima T; Miyazaki M; Sumida H; Akamata K; Takahashi T; Ichimura Y; Toyama T; Sugita M; Noda S; Yao A; Kinugawa K; Sato S
Br J Dermatol; 2012 Feb; 166(2):417-21. PubMed ID: 21848685
[TBL] [Abstract][Full Text] [Related]
14. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
Schiopu E; Hsu VM; Impens AJ; Rothman JA; McCloskey DA; Wilson JE; Phillips K; Seibold JR
J Rheumatol; 2009 Oct; 36(10):2264-8. PubMed ID: 19755613
[TBL] [Abstract][Full Text] [Related]
15. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.
Kuhn A; Haust M; Ruland V; Weber R; Verde P; Felder G; Ohmann C; Gensch K; Ruzicka T
Rheumatology (Oxford); 2010 Jul; 49(7):1336-45. PubMed ID: 20371505
[TBL] [Abstract][Full Text] [Related]
16. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
17. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
[TBL] [Abstract][Full Text] [Related]
18. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.
Hettema ME; Zhang D; Bootsma H; Kallenberg CG
Ann Rheum Dis; 2007 Oct; 66(10):1398-9. PubMed ID: 17881663
[No Abstract] [Full Text] [Related]
19. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.
Matucci-Cerinic M; Denton CP; Furst DE; Mayes MD; Hsu VM; Carpentier P; Wigley FM; Black CM; Fessler BJ; Merkel PA; Pope JE; Sweiss NJ; Doyle MK; Hellmich B; Medsger TA; Morganti A; Kramer F; Korn JH; Seibold JR
Ann Rheum Dis; 2011 Jan; 70(1):32-8. PubMed ID: 20805294
[TBL] [Abstract][Full Text] [Related]
20. The effect of the endothelin-1 receptor antagonist, bosentan, on patients with poorly controlled asthma: a 17-week, double-blind, placebo-controlled crossover pilot study.
Coyle TB; Metersky ML
J Asthma; 2013 May; 50(4):433-7. PubMed ID: 23363065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
